Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

Trial Profile

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veverimer (Primary)
  • Indications Metabolic acidosis; Renal failure
  • Focus Registrational; Therapeutic Use
  • Acronyms VALOR-CKD
  • Sponsors Tricida
  • Most Recent Events

    • 14 Nov 2019 According to a Tricida media release, 95% of the approximately 350 targeted sites are open for enrollment and enrollment is expected to complete in mid-2020.
    • 08 Aug 2019 According to a Tricida media release, the overall status and rate of enrollment of this trial were deemed sufficient by the FDA for the company to plan for the NDA submission for veverimer in the third quarter of 2019. The company intends to provide an update by the end of 2019 on its estimate for enrolling the last patient in its postmarketing trial.
    • 25 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top